Kornimate/medical-research-clean huggingface dataset:
survival of root canal treated teeth restored with ceramic onlays

Conditions: Dental Pulp Diseases

Summary: advances in digital dentistry coupled with increased demand for aesthetic restorations have led to developments in cad cam( computer aided design and computer aided manufacturing)systems for manufacturing tooth restorations. cad cam restorations have the added benefit of digital impressions which eliminate the need to take conventional impressions, something patients find difficult to tolerate. cad cam restorations are now part of routine dental care. however there are no clinical studies evaluating these restorations on root canal treated teeth this study aims to compare the success and survival of root canal treated teeth and/or restoration with varying degrees of tooth structure loss restored using cad cam restorations. null hypothesis:- the amount of residual coronal dentin has no effect on the survival of root canal treated teeth and/or restoration.

this study will be carried out at kcl dental institute at guy's hospital and will form part of the routine dental treatment done at the endodontic postgraduate unit. potential volunteers will be given written information about the process and be given time to consider participation. once any questions have been answered, fully informed written consent will be obtained if they are interested in taking part. patients requiring endodontic treatment with varying degrees of tooth structure loss will be detected, diagnosed and treated by endodontic mclindent postgraduate students at guy's hospital using suitable clinical techniques. the teeth will then be restored using cad cam restorations. dental periapical radiograph and cone beam computed tomography (cbct)scans (morita accuitomo) will be taken at baseline, 12 months and 24 months. clinical assessment and radiographical evaluation will be carried out immediately after endodontic treatments have been accomplished and 1 and 2 years post treatment and will be assessed independently by a group of examiners. it is hoped that data analysed from this study will provide a definitive clinical evidence base for the success and survival of endodontically teeth and/or restorations.

Eligibility criteria:
inclusion criteria: 1. patients either male or female over the age of 18 (who can consent for themselves) in good general health. 2. the selected teeth needed to be in occlusal function with a natural tooth and in interproximal contact with two adjacent natural teeth. 3. molar or premolar teeth with suspected endodontic problems that require root canal treatment. 4. teeth should not be mobile and must be restorable. exclusion criteria: 1. pregnant women, in view of requirements for radiographs (or if they could possibly be pregnant). to be confirmed by the medical history questionnaire. 2. patients younger than 18. 3. patients unable to give consent. 4. teeth with probing periodontal depths greater than 5 mm. 5. non-restorable teeth. 6. not involving patients from prisons. 7. not involving patients who cannot read, write or understand english
eldecalcitol and calcitriol in postmenopausal women with low bone mineral density or mild osteoporosis

Conditions: Low Bone Mineral Density; Postmenopausal Osteoporosis

Summary: to investigate the efficacy and safety of eldecalcitol in postmenopausal women with low bone mineral density (bmd) or mild osteoporosis through a randomized, open-label, parallel controlled trial with calcitriol as the control.

postmenopausal women with low bone mineral density (bmd) or mild osteoporosis will be randomized in a 1:1 ratio to receive open-label oral 0.75μg eldecalcit daily or open-label oral 0.5μg calcitriol daily for 12 months.

Eligibility criteria:
inclusion criteria: 1. postmenopausal women (based on medical history) aged 50 or older and menopause time more than 2 years. if there is uncertainty regarding menopausal status, women 60 years of age and older will be considered postmenopausal. 2. bmd (determined by dxa) of lumbar l1-4 or total hip or femoral neck met one of the following conditions at screening: 1) low bmd: -2.5\<t\< -1.0, without vertebral and fragility fracture history 2) mild osteoporosis: t≤-2.5, without vertebral and fragility fracture history 3. ambulatory outpatients 4. written informed consent exclusion criteria: 1. severe vitamin d deficiency at screening (defined as serum 25ohd\<10 ng/ml);vitamin d repletion will be permitted and dosage will be at the discretion of investigators and subjects may be re-screened 2. primary hyperparathyroidism, cushing's syndrome, hyperthyroidism, gonadal insufficiency, osteogenesis impotence, rheumatoid arthritis, poorly controlled diabetes mellitus (hba1c\>9%), or other conditions that can cause secondary osteoporosis, or treatment with glucocorticoids in the 2 months prior to study entry 3. had injected bisphosphonate once or more within 3 years before entering the study; or had received oral bisphosphonate oral for 6 months or more in the 3 years prior to study entry; or had received parathyroid hormone once or more in the 3 years before entering the study; or received 2 weeks or more of calcitonin or vitamin k or active vitamin d or selective estrogen receptor modulator or hormone replacement therapy or traditional chinese medicine for bone pine within 2 months prior to study entry; or received subcutaneous anti-rankl antibody at any time prior to study entry 4. urolithiasis at screening 5. hypercalcemia (serum calcium \>10.4 mg/dl), or hypercalciuria (urine calcium\>400 mg/gcr), or hyperuricemia (above 420 μmol/l in men and 360 μmol/l in women) 6. severe liver disease such as cirrhosis or serious heart disease such as severe heart failure 7. active malignant tumors or a history of malignant tumors within 5 years before informed consent obtained 8. history of allergy to vitamin d 9. any condition which in the opinion of the investigator unfit for the study
freezing of gait and cognition

Conditions: Gait Disorder, Sensorimotor; Cognition Disorders; Parkinson Disease

Summary: the study was aimed to investigate the role of cognition n in fog.

alteration of cortical circuits in pd leads to cognitive dysfunctions associated with the development of fog. the study was aimed to investigate the role of cognition in fog.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease according to gelb et al. exclusion criteria: * any other neurological conditions other than pd
accuracy of holladay 2 formula in the absence of lens thickness

Conditions: Cataracts

Summary: hypothesis: holladay 2 formula is still accurate even used without lens thickness data.


Eligibility criteria:
inclusion criteria: * patients with cataract exclusion criteria: * previous ocular diseases * previous ocular surgery
methylene blue in severe sepsis and septic shock

Conditions: Severe Sepsis; Septic Shock

Summary: this study is to see whether the intravenous administration of methylene blue improves the outcome in severe sepsis and septic shock.

the mortality of septic shock is still high ranging from 30 to 50%. vasopressor is the main part in managing septic shock, but the choice of vasopressor is still under-investigated, and area of uncertainty. the response to vasopressor is sometimes unsatisfactory, and in that case, the outcome of the patients is poor. recently, small size clinical trial has investigated the effect of methylene blue (mb), and showed promising results. however, large sized phase iii trial has not been performed yet. large sized phase iii clinical trial is needed to establish the effect of mb in septic shock.

Eligibility criteria:
inclusion criteria: * septic shock meeting the criteria of 2012 surviving sepsis campaign * need the norepinephrine of over 0.2microgram/kg/min exclusion criteria: * pregnancy * less than 18 years old * terminal cancer patients * declined consents * glucose-6-phosphate dehydrogenase deficiency * medication of serotonin modulator

Keywords: sepsis septic shock methylene blue
effect of pirfenidone on glomerular filtration rate and albuminuria in patients with diabetic nephropathy

Conditions: Diabetic Nephropathy; Albuminuria

Summary: it is estimated that approximately 30% of patients with diabetes develop diabetic nephropathy. diabetic nephropathy is a multifactorial progressive disease that occurs through various mechanisms such as hyperglycemia, oxidative stress, inflammation and fibrosis, control or blocking these mechanisms are therefore potential therapeutical targets for this entity. current treatment options are based on the glycemic control, blood pressure control, as well as the use of medications such as angiotensin-converting enzyme inhibitors and angiotensin ii receptor antagonists, these actions are not enough to stop progression. pirfenidone is a drug with antifibrotic, antioxidant, and anti-inflammatory properties. although the specific mechanism is unknown, pirfenidone interferes with the expression, secretion and the effect of the β (tgf-β) transforming growth factor. the investigators plan to carry out a controlled clinical study to evaluate the effect of pirfenidone in patients with type 2 diabetes and nephropathy. the period of time the treatment will be administered will be of 12 months, 62 patients will be included. the primary outcome will be improvement in glomerular filtration rate. the secondary outcomes will be number of patients requiring replacement therapy, 24 hour urine microalbuminuria and change in the concentration of tgf - β. change in these parameters will be evaluated at the end of the treatment period (12 months). throughout the study the incidence of adverse events will be recorded, wich will allow us to learn about the safety and security of the drug in this population.


Eligibility criteria:
inclusion criteria * body mass index (bmi) less than 35 kg/m2 * diagnosis of diabetes mellitus type 2 * glomerular filtration rate of 15-89 ml/min * albuminuria ≥30 mg/24 h and \< 3.5 g/24 h * individuals with blood pressure less than 140/90 mmhg or treated with stable doses of anti-hypertensive drugs. * glycated hemoglobin \<10% exclusion criteria * another etiology of renal disease (autoimmune diseases, polycystic kidney disease) * repeated urinary tract infections (more than three episodes in the past year) * photosensitivity to any drug * liver disease * pregnancy * breastfeeding

Keywords: pirfenidone diabetic nephropathy
comparative study of alternative antiandrogen (aa) therapy and early initiating of enzalutamide for castration-resistant prostate cancer (crpc) after combined androgen blockade (cab) therapy.

Conditions: Castration-resistant Prostate Cancer

Summary: the objective of this study is to compare the efficacy and safety of enzalutamide or alternative aa therapy in crpc participants who were previously treated with a combined androgen blockade therapy which included bicalutamide (bic-cab). efficacy and safety of enzalutamide and alternative aa therapy will be evaluated, and effective therapy against crpc after treatment with bic-cab will be investigated.


Eligibility criteria:
inclusion criteria: * testosterone of less than 50 ng/dl * participants who was detected of disease progression on image or relapse of psa (all psa values measured 3 time at least one week interval are consecutively increased and final value is 2 ng/ml or more. if third value is not higher than second one, fourth measurement will be undertaken and its value must be higher than second one.) * participants who relapsed after cab with bicalutamide * eastern cooperative oncology group (ecog) performance status is 0 or 1 * aged 20 years or older * participants who provided written informed consent exclusion criteria: * any prior treatment with enzalutamide, flutamide, abiraterone or chemotherapy, except for neoadjuvant therapy * with active double cancer * any prior treatment with bicalutamide within 6 weeks * participants who received systemic biological therapy (except for existing approved drug for bone or treatment with luteinizing hormone-releasing hormone (lhrh) analogue) or received treatment with other antitumor agent for prostate cancer * with serious complication * history of hypersensitivity to enzalutamide or any other excipient of enzalutamide * history of hypersensitivity to flutamide-containing agent * with liver dysfunction * participants who are considered as inadequate by the investigator
effectiveness intraarticular corticosteroid

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to compare the small and large dose of corticosteroid used in intraarticular injection of wrist.

background / objectives: the optimal dose of corticosteroid to be used in intraarticular injection is not well established. the objective of this study is to compare the effectiveness and tolerance in the medium-term between small and large dose of triamcinolone hexacetonide (th) used in intraarticular injection (iai) of medium size joint of patients with rheumatoid arthritis (ra). materials/methods: a controlled, randomized, prospective, double-blind study will be realized in patients with ra. it will be evaluated 60 wrists joints (representing medium size joints) from the outpatient clinics at the rheumatology division unifesp, brazil. inclusion criteria were: patients with established ra, age between 18 and 65 years, disease modifying anti-rheumatic drugs (dmards) stable for at least 3 months, synovitis in wrist with pain visual analogic scale (vas) between 4 and 8cm. patients with overlap syndromes, polyarticular synovitis, diabetes mellitus or uncontrolled hypertension and those with suspected local or systemic infection were excluded. patients will be randomized (clapboard randomization) in two groups of 30 patients each: group 1 (high dose) is injected with 40mg (2ml) of th and group 2 (small dose) was injected 20mg (1ml). only one joint is injected by patient (iai blindly). evaluation will be conducted by a blinded observer at five times: baseline (t0), one week (t1), four (t4), eight (t8) and twelve (t12) weeks and the following assessment instruments were used: visual analogue scale for pain and swollen (vas 0-10cm); wrist goniometry; chronic disease activity index (cdai). side effects and related events were reported in a medical questionnaire. the level of statistical significance was 5%.

Eligibility criteria:
inclusion criteria: * patients with established ra * age between 18 and 65 years * disease modifying anti-rheumatic drugs (dmards) stable for at least 3 months * synovitis in wrist with pain visual analogic scale (vas) between 4 and 8cm exclusion criteria: * patients with overlap syndromes * polyarticular synovitis * diabetes mellitus or uncontrolled hypertension and those with suspected local or systemic infection

Keywords: injection arthritis corticosteroid
efficacy of ultrasound contrast agent to assess renal masses

Conditions: Renal Cell Carcinoma

Summary: patients with an incidentally discovered small renal masses (srm) \< 4 cm in diameter are included. all patients will undergo biopsy for tissue diagnosis. most patients will be followed by imaging. study intervention includes low mi us to be performed following both bolus and infusion injection of definity contrast. presence and absence of vascularity, pattern of vascularity, and tic values will be correlated with the final pathology to find features differentiating benign from malignant masses.


Eligibility criteria:
inclusion criteria: * patients with newly diagnosed renal mass \< 4 cmm, who are going to undergo diagnostic ct, mri or biopsy.

Keywords: small renal mass contrast enhanced ultrasound renal cell carcinoma noninvasive diagnosis of rcc
role of parecoxib sodium for postoperative pain management in open hepatectomy

Conditions: Hepatic Hemangioma Located in the Right Liver; Laparotomy Surgery

Summary: to searching the role of parecoxib sodium for postoperative pain management in open hepatectomy


Eligibility criteria:
inclusion criteria: * age between 20-70 years old; * hepatic hemangioma patients who will undergo laparotomy surgery: diameter of hepatic hemangioma between 5-15cm, located in the right liver; * child score 5-6; * bmi: 19-25; * asa: ⅰ \~ ⅱ grade; * no comorbidities such as diabetes, hypertension, cardio renal or respiratory dysfunction, mental illness; * no known allergies; * no participation in other clinical trials within 2 months; * have been informed consent. * surgery-related: right subcostal incision, surgical time\< 4 hours, hepatic pedicle occlusion time\< 20 minutes, bleeding\< 1000ml, no blood transfusions. exclusion criteria: * history of chronic pain，long-term use of analgesic drugs or alcohol abuse; * allergic to nsaids, opioids or sulfa drugs; * coagulopathy or other hematological disorder； * active peptic ulcer, gastrointestinal bleeding, inflammatory bowel disease; * pregnant or lactating; * mentally unstable to use pca; * preoperative pain caused by other disease; * analgesic drugs or nsaids intake one week before surgery; * preoperative systemic inflammatory response syndrome; * preoperative chemotherapy or radiotherapy; * preoperative or postoperative use of steroids; * operative time\> 4 hours, hepatic pedicle occlusion time\> 20 minutes, blood loss\> 1000ml, or intraoperative blood transfusion; * tbil\> 34 umol/l、pt prolongation\> 3s、alb\ 7 within 42 hours after surgery； * bleeding、biliary fistula, intra-abdominal infections or other postoperative complications.
evaluation of the efficacy of topical ophthalmic steroids in a modified conjunctival allergen challenge (cac) model

Conditions: Allergic Conjunctivitis

Summary: to evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (tears naturale® ii) in the prevention of the signs and symptoms of allergic conjunctivitis. comparisons will be made following 1 week of twice daily (bid) dosing and 1 week of four times daily (qid) dosing.

structure: prospective, single center, randomized, double-masked, parallel treatment comparison study. subjects will be randomized to one of the following treatment arms to be dosed bilaterally twice daily (bid) for the first dosing period and four times daily (qid) for the second dosing period: 1. prednisolone acetate 1% ophthalmic suspension 2. prednisolone acetate 0.12% ophthalmic suspension 3. loteprednol etabonate 0.2% ophthalmic suspension 4. tears naturale® ii duration: approximately four (4) weeks controls: artificial tears (tears naturale® ii)

Eligibility criteria:
inclusion criteria: * at least 18 years of age \& either sex, any race * willing and able to follow all instructions * positive history of ocular allergies * reproducible positive ocular allergic reaction induced by conjunctival allergen challenge exclusion criteria: * have planned surgery during trial period * female currently pregnant, planning a pregnancy or lactating * use of disallowed medications * have ocular infections, or ocular conditions that could affect study parameters * have moderate to severe dry eye * have used an investigational drug or device within 30 days of start of study * female that is currently pregnant, planning a pregnancy or lactating

Keywords: allergic conjunctivitis
timing of prophylactic antibiotics for cesarean sections

Conditions: Endometritis; Wound Infection

Summary: this is a randomized, double-blinded placebo controlled trial of cefazolin timing before cesarean section fo infection prophylaxis. subjects are randomized to cefazolin either 30 minutes prior to skin incision or at time of cord-clamping. primary outcome is infectious morbidity including wound infections and endometritis.


Eligibility criteria:
inclusion criteria: pregnant 24-43 weeks gestation \> 18 years old requiring cesarean section - exclusion criteria: receiving antibiotics \< 18 years old allergy to cefazolin -

Keywords: cesarean section antibiotic prophylaxis cefazolin
evaluation of the safety and effectiveness of the dexcom continuous glucose monitoring (cgm) system

Conditions: Diabetes Mellitus

Summary: evaluation of the safety and effectiveness of the dexcom glucose monitoring (cgm) system

the objective of this study is to establish performance of the dexcom cgm system (system) in comparison to a blood glucose comparator method.

Eligibility criteria:
inclusion criteria: * ages 2 or older * diagnosis of type 1 diabetes or type 2 diabetes * willing to wear the required number of systems for the total duration of study wear * willing to participate in clinic session(s) during study wear exclusion criteria: * presence of extensive skin changes/diseases at sensor wear site(s) that preclude wearing the sensor(s) on skin * known allergy to medical-grade adhesives * pregnancy * hematocrit outside specification * ≥ 18 years of age: * male: 36.0%; * female: 33.0%; * 13-17 years of age: 35.0%; * 7 years - 12 years of age: 32.0%; * end stage renal disease and currently managed by dialysis or anticipating initiating dialysis during the study wear period * required or scheduled to have a magnetic resonance imaging (mri) scan, computed tomography (ct) scan, or diathermy during the study wear period
clinical comparison of 2 daily disposable contact lenses - pilot study 1

Conditions: Refractive Errors; Myopia

Summary: the primary objective of this study is to evaluate the overall performance of precision1 contact lenses when compared to biotrue oneday contact lenses.

subjects are expected to attend 3 study visits and wear the precision1 and biotrue oneday study lenses in a crossover design for approximately 8 days of exposure to each study lens type. the expected duration of subject participation is up to 22 days.

Eligibility criteria:
key inclusion criteria: * subject must be able to understand and must sign an institution review board (irb) approved informed consent form. * successful wear of spherical soft contact lenses in both eyes for a minimum of 5 days per week and 10 hours per day during the past 3 months. * willing to wear contact lenses for at least 16 hours per day on one of the days with each lens type. * other protocol-specified inclusion criteria may apply. key exclusion criteria: * any ocular condition that contraindicates contact lens wear. * previous or current habitual wearer of precision1, biotrue oneday, or dailies total1 contact lenses. * other protocol-specified exclusion criteria may apply.

Keywords: daily disposable contact lenses